Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Compass PathwaysCMPS -3.84%32 Return-on-Tangible-Asset is 98.32% as of Mar. 2026. GuruFocus rates CMPS with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 679 Healthcare Providers & Services companies, Compass Pathways ranks worse than 86.45% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Compass Pathways's annualizedNet Income for the quarter that ended in Mar. 2026 was $364.81 Mil. Compass Pathways's average total tangible assets for the quarter that ended in Mar. 2026 was $371.04 Mil. Therefore, Compass Pathways's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 98.32%.
The historical rank and industry rank for Compass Pathways's Return-on-Tangible-Asset or its related term are showing as below:
CMPS'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -135.78 Med: -50.63 Max: -28.45
Current: -55.51
During the past 8 years, Compass Pathways's highest Return-on-Tangible-Asset was -28.45%. The lowest was -135.78%. And the median was -50.63%.
CMPS's Return-on-Tangible-Asset is ranked worse than 86.45% of 679
companies
in the Healthcare Providers & Services industry
Industry Median: 2.51
vs CMPS: -55.51
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Compass Pathways Return-on-Tangible-Asset Related Terms
Compass Pathways Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Compass Pathways's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMPS vs AGL, MD, SEM: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, Compass Pathways's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 98.32% mean?
Compass Pathways (CMPS) has a Return-on-Tangible-Asset of 98.32% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Compass Pathways and its competitors. According to the industry distribution chart, Compass Pathways ranks #587 out of 679 companies in the Healthcare Providers & Services industry, placing it in the top 86.5%.
Is Compass Pathways' Return-on-Tangible-Asset too high?
Compass Pathways' current Return-on-Tangible-Asset is 98.32%. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.51. Compass Pathways' value of 98.32% is 3817.1% above this industry median. Based on the distribution chart, Compass Pathways ranks #587 out of 679 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Compass Pathways has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Compass Pathways' Return-on-Tangible-Asset compare to AGL and MD?
According to the Healthcare Providers & Services industry distribution chart, Compass Pathways ranks #587 out of 679 companies for Return-on-Tangible-Asset. This places Compass Pathways in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.51. Compass Pathways' value of 98.32% is 3817.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.51, based on 679 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compass Pathways's current Return-on-Tangible-Asset of 98.32% is 3817.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Compass Pathways and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compass Pathways's current Return-on-Tangible-Asset is 98.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Pathways stock overvalued right now?
Compass Pathways (CMPS) has a current Return-on-Tangible-Asset of 98.32%. The current Return-on-Tangible-Asset is 98.32% and 3817.1% above the Healthcare Providers & Services industry median of 2.51. Compass Pathways' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Compass Pathways (CMPS), the current Return-on-Tangible-Asset is 98.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
32GF Score
Get the complete analysis for CMPS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMPS has been successfully added to your 
